SYNBIOTIC keeps expanding its presence in the cannabis and hemp industry
|
EQS-News: SYNBIOTIC SE
/ Key word(s): Conference/Statement
Successful roadshow continues: SYNBIOTIC keeps expanding its presence in the cannabis and hemp industry
The European medical cannabis and industrial hemp group SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) is increasingly benefiting from its strong visibility and attention in the cannabis industry - and investors and shareholders are also benefiting from this. "We are currently holding discussions on all channels with existing and potential investors who have become aware of us and our business model through our presence at various events," says Daniel Kruse, Managing Director of SYNBIOTIC. "And we will continue to pursue this high-profile strategy." Talman House and ICBC In April 2025, SYNBIOTIC and GOC NEXUS presented their strategic partnership to international investors at the Talman event "Shape the Future of Cannabis Investment" in Berlin. Immediately afterwards, SYNBIOTIC, GOC NEXUS and WEECO Pharma exhibited at the ICBC in Berlin. Talman House is a members-only service that connects investors with successful cannabis companies in Europe and around the world. The International Cannabis Business Conference (ICBC) is the largest B2B event for political and business leaders in the cannabis industry in Europe. BvCW, EIHA and Mary Jane In May 2025, SYNBIOTIC sponsored the Parliamentary Evening of the German Cannabis Industry Association (BvCW) in Berlin. In June 2025, the group of companies will once again be represented at two events in the German capital: the European Industrial Hemp Association (EIHA) conference and Mary Jane, the world's largest cannabis event. Daniel Kruse will be attending the 22nd conference of the European Industrial Hemp Association from 11 to 13 June 2025 at the Dorint Kurfürstendamm in a dual function: firstly as Managing Director of SYNBIOTIC and secondly as President of the European Industrial Hemp Association (EIHA). The conference is regarded as one of the largest of its kind on the subject of industrial hemp worldwide. Kruse will be speaking on topics including "Germany: a new regulatory approach". SYNBIOTIC is also involved as an exhibitor. From 19 to 22 June 2025, over 500 exhibitors from all over the world will be presenting at Mary Jane on the exhibition grounds in Berlin. SYNBIOTIC will be part of this largest and unique cannabis event in the world with a team on site. The organisers are expecting over 60,000 visitors. SYNBIOTIC will be taking part in a panel on "Building a cannabis industry - experiences and assessments" as part of the cannabis industry conference taking place at the same time, and SYNBIOTIC subsidiary Cannexo will be taking part in a panel on "Cuttings, seeds, cultivation equipment - quality standards in home cultivation". Cannabis and Hemp in Germany - what's next? On 23 February 2024, the German Bundestag passed the Act on the Controlled Use of Cannabis and on the Amendment of Other Regulations (Cannabis Act). On 22 March 2024, the Cannabis Act (KCanG) was discussed and approved by the Federal Council. In order to assess the impact on society, an accompanying close-meshed evaluation is planned. This "open-ended evaluation" announced by the new federal government in its coalition agreement is due to start in October 2025. "Cannabis and hemp are increasingly being used as a versatile tool to tackle some of the biggest challenges of our time - from chronic pain to reducing CO2 emissions. We need to improve the legal frameworks, which are decades behind science. Cannabis must be treated as what it is: a medicine. Hemp must be treated as what it is: an industrial crop," says Daniel Kruse, CEO of SYNBIOTIC. Publisher SYNBIOTIC SE Daniel Kruse Managing Director Münsterstrasse 336 40470 Düsseldorf Germany www.synbiotic.com Media Contact Rüdiger Tillmann SYNBIOTIC Public Relations Manager E-Mail ruediger.tillmann@synbiotic.com Mobile +49 170 9651451 c/o JOLE.group About SYNBIOTIC SYNBIOTIC is a listed group of companies in the medical cannabis and industrial hemp sector with a buy-and-build investment strategy focussed on Europe. The Group covers the entire value chain from cultivation to production and retail - from the field to the shelf. The subsidiaries' core businesses are research and development, production and the commercialisation of medical cannabis, industrial hemp and CBD products. SYNBIOTIC is pursuing a clear pan-European strategy of further expanding its business areas in order to cover the relevant growth markets while minimising risks and increasing opportunities for investors through diversification.
11.06.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | SYNBIOTIC SE |
| Münsterstr. 336 | |
| 40470 Dusseldorf | |
| Germany | |
| E-mail: | office@synbiotic.com |
| Internet: | https://www.synbiotic.com/ |
| ISIN: | DE000A3E5A59 |
| WKN: | A3E5A5 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange |
| EQS News ID: | 2153746 |
| End of News | EQS News Service |
|
|
2153746 11.06.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.